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Abstract
Post-translational modification of proteins by ADP-ribosylation, catalysed by poly (ADP-ribose) polymerases
(PARPs) using NAD+ as a substrate, plays central roles in DNA damage signalling and repair, modulates a range of
cellular signalling cascades and initiates programmed cell death by parthanatos. Here, we present mechanistic as-
pects of ADP-ribose modification, PARP activation and the cellular functions of ADP-ribose signalling, and discuss
how this knowledge is uncovering therapeutic avenues for the treatment of increasingly prevalent human diseases
such as cancer, ischaemic damage and neurodegeneration.
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PARP members, structure and activity
ADP-ribosyl transferases, also known as poly(ADP-
ribose) polymerases (PARPs), are specific enzymes that
transfer the ADP-ribose moiety from -nicotinamide ade-
nine dinucleotide (NAD+) to a target macromolecule, main-
ly proteins. This activity was identified in the 1960s
(Chambon et al., 1963), and almost 20 years later, single-
and double-strand DNA breaks were determined as enzyme
activators in cell extracts (Benjamin and Gill, 1980a;
1980b). Since then, ADP-ribosylation of proteins has been
recognized as a central posttranslational modification in a
range of cellular processes, such as DNA damage signal-
ling and repair, transcription, Wnt signalling and program-
med cell death (Gibson and Kraus, 2012; Virag, 2013;
DaRosa et al., 2015; Kraus, 2015).
ADP-ribosylation can occur either as a single
mono(ADP-ribose) unit (MAR) or as poly(ADP-ribose)
(PAR) chains, which can be linear or branched. Since the
ADP-ribosyl (ADPr) group contains a high density of nega-
tive charges, the addition of ADPr units can dramatically
change the biophysical properties of a target protein or pro-
mote protein-protein interactions (Figure 1). For example,
long PAR chains have been proposed to produce a halo of
negatively charged density around the target protein, dis-
rupting the liquid phase in which the protein is embedded
(Altmeyer et al., 2015).
There are 17 known members of the PARP family in
the human genome (Barkauskaite et al., 2015), and most of
these possess the ability to auto-modify, often on multiple
sites (Vyas et al., 2014). However, only a few are bona fide
poly(ADP-ribose) polymerases, while most are in fact
mono(ADP-ribosyl) transferases (Vyas et al., 2014). In hu-
man cells, the majority of PARP activity is exerted by
PARP1 (85%-90%) and by PARP2 (10%–15%) (Szanto et
al., 2012).
PARPs are multidomain proteins that contain a com-
mon structurally related catalytic domain that is also found
in a range of pathogenic toxins from both gram-positive
and gram-negative bacteria such as Bacillus sphaericus,
Clostridium sp., Corynebacterium diphteriae, Salmonella
enterica, Vibrio cholera and Escherichia coli, (Laing et al.,
2011; Karlberg et al., 2013; Simon et al., 2014; Barkaus-
kaite et al., 2015; Langelier et al., 2018). The catalytic do-
mains of 5 of the 17 human members – PARP1, 2, 3, 4 and
16 –, contain an additional subdomain known as helical
domain (HD), which has autoinhibitory functions by steri-
cally hindering NAD+ binding and has to be removed for
every catalytic cycle (Dawicki-McKenna et al., 2015; Lan-
gelier et al., 2018).
Reaction mechanism
The PARP1 active site is formed between the cata-
lytic domain (ART domain) and the helical domain (HD)
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Figure 1 - Schematic mechanism of ADP ribosylation reaction and the catalytic domain of DNA-dependant PARPs. A) A simplified overview of the
(ADP)-ribosylation reactions catalysed by PARPs. The final products depend on the acceptor residue acting as a nucleophile (Nu, in blue). PARP1 ac-
tive-site residues interacting with the ribose-nicotinamide moiety of NAD+ are illustrated in orange. B) The NAD+ (modelled based on the human PARP1
bound to benzamide adenine dinucleotide [PDB: 6BHV], carbon atoms in yellow) in an extended conformation, bound to the catalytic domain of human
PARP1 (ART in cartoon, orange, [PDB: 6BHV]). The residues involved in the catalysis are presented as sticks. C) Superposed cartoon view of human
PARP-1 ART domain (orange, [PDB: 6BHV]), PARP1 (light blue, [PDB: 5WS1]) and PARP2 (green, [PDB: 3KJD]) showing the structure of the entire
catalytic domains (ART and HD). The modelled NAD+ (in yellow) denotes the donor site, while a molecule of ADP (modelled by superimposing the
structures of chicken PARP1 [PDB: 1A26] to the human PARP1 [PDB: 3KJD]) indicates the acceptor site. Donor loop (D-loop) and acceptor loop are la-
belled. D) Surface representation of human PARP1 [PDB: 3KJD] with NAD+ modelled into the active site. The ribose group to be attacked is exposed to
the solvent.
(Figure 1B, C). The substrate to be PARylated binds to the
acceptor site on the surface of the ART domain, defined by
the acceptor loop (residues 977 to 988 in PARP1) that is
also thought to regulate polymer length and chain branch-
ing (Vyas et al., 2014; Chen et al., 2018). NAD+ binds to
the donor site in an extended conformation, such that the
ADP-ribose moiety interacts with the D-loop in the ART
domain (residues 875 to 894 in PARP1) (Gibson and Kraus,
2017), while the nicotinamide moiety forms three hydrogen
bonds with Gly863, Ser904 and Tyr907 (PARP1 number-
ing) (Figure 1B, C) (Langelier et al., 2018).
Two reaction mechanisms have been proposed, with
detailed structural evidence supporting the second mecha-
nism (Tsurumura et al., 2013). One is an SN2 displacement
mechanism, with the formation of a penta-coordinated tran-
sition state (Marsischky et al., 1995), while the other is an
SN1 strain-alleviation mechanism that involves the forma-
tion of a stable furanosyl oxocarbenium ion (van Rijssel et
al., 2014), and a rotation around the phosphodiester bond
(Simon et al., 2014; Cohen and Chang, 2018). In either
case, the nucleophilic attack is performed by an oxygen or a
nitrogen atom from the side chain of the target amino acid,
which can be glutamic acid, aspartic acid, serine, cysteine,
arginine, lysine or tyrosine (Ogata et al., 1980; Altmeyer et
al., 2009; Laing et al., 2011; Rosenthal and Hottiger, 2014;
Bonfiglio et al., 2017; Leslie Pedrioli et al., 2018). Subse-
quently, the product can have chemical reorganisations:
glutamate and aspartate modifications undergo a C1’–C2’
transfer, and lysine linkages suffer an Amadori rearrange-
ment to form a stable ketoamine (Altmeyer et al., 2009;
Morgan and Cohen, 2015; Cohen and Chang, 2018) (Figure
1A). Ultimately, nicotinamide is released as a by-product.
Linear PAR chains are formed using the hydroxyl group in
C2 of the ADP-ribose moiety, and branching involves the
oxygen in C2’ for the nucleophilic attack (Juarez-Salinas et
al., 1982; Chen et al., 2018).
Recently, an important modifier of PARP catalytic
activity, termed histone PARylation factor (HPF1), was de-
scribed (Gibbs-Seymour et al., 2016). HPF1 is responsible
for switching specificity of PARP1/2 towards serine and ty-
rosine residues and from auto-PARylation to PARylation
of chromatin components and remodellers (Bonfiglio et al.,
2017; Leslie Pedrioli et al., 2018). HPF1 also seems to
modulate the length of ADPr polymers and can itself be
mono(ADP)ribosylated by PARP1 (Leslie Pedrioli et al.,
2018). Recent studies revealed that serine could be the pre-
dominant PARylation site at chromatin after DNA damage
(Leidecker et al., 2016; Palazzo et al., 2018). Strikingly,
some results indicate that despite the presence of a hydro-
xyl group and the resemblance with serine, threonine is not
modified by PARP in mammalian cells (Leslie Pedrioli et
al., 2018).
Domain architecture and activation
In addition to the catalytic domain, PARPs contain
different domains that mediate protein-protein or protein-
nucleic acid interactions, such as ankyrin repeats (PARP5a
and 5b, called tankyrases); CCCH zinc fingers (PARP7, 12
and 13), and macrodomains (PARP9, 14 and 15) (Gibson
and Kraus, 2012; Karlberg et al., 2013; Barkauskaite et al.,
2015). The DNA-dependent PARPs 1, 2 and 3 have DNA
binding domains that promote their activation by DNA
breaks. These proteins contain a WGR (Trp-Gly-Arg) do-
main, which upon DNA binding promotes conformational
changes in the HD that activate the catalytic domain (Eus-
termann et al., 2015; Grundy et al., 2016; Obaji et al.,
2018).
In PARP1, the WGR domain is not involved in the
initial recognition and binding of DNA-breaks (Euster-
mann et al., 2015). Instead, three zinc fingers (ZnFs) make
the primary contact with the DNA. The first two ZnFs at the
PARP1 N-terminus are necessary and sufficient for protein
recruitment to DNA-damage sites in vivo, using structur-
ally equivalent residues (Ali et al., 2012). Recent NMR
studies suggest that ZnF2 is the leading domain that binds
to the 3’ end of the break, followed by ZnF1, which recog-
nises the 5’ end. This complex promotes ZnF3 recruitment,
which leads to WGR domain binding to a surface formed
by ZnF1, ZnF3 and DNA (Eustermann et al., 2015). Inter-
estingly, PARP1 makes much more extensive contacts with
the DNA surrounding the break than at the break site per se,
allowing for the recognition of DNA breaks from a variety
of sources. In contrast, the WGR domains of both PARP2
and PARP3 (which do not have ZnFs) play a key role in
DNA binding and discriminate between different DNA
ends by recognising the presence of a 5’phosphate group at
the DNA break site (Langelier et al., 2014; Grundy et al.,
2016; Obaji et al., 2018).
In addition to the domains involved in DNA-break
recognition and catalytic activation, PARP1 contains a
BRCT-like (BRCA1 C-terminus) domain where most of
the auto-modification sites have been identified (Altmeyer
et al., 2009; Tao et al., 2009) and which is implicated in me-
diating protein-protein interactions (Liu et al., 2011; Noren
Hooten et al., 2011; Hsu et al., 2019)
ADP-ribosylation of DNA
ADP-ribosylation was long considered a protein mo-
dification exclusively. However, recent reports have inde-
pendently shown that DNA-dependent PARPs can add
ADPr covalently to DNA ends, at least in vitro (Talhaoui et
al., 2016; Munnur and Ahel, 2017; Zarkovic et al., 2018).
PARP1, PARP2 and PARP3 all modify both 3’ or 5’
terminal phosphate groups via a phosphodiester bond, and
PARP1 and PARP2 can also modify free 3’hydroxyl
groups to generate a ribose-ribose bond (Talhaoui et al.,
2016; Munnur and Ahel, 2017; Zarkovic et al., 2018).
Modification of 5’ phosphorylated ends may protect them
from phosphatase activity, offering a possible function for
this modification in vivo. Surprisingly, ADP-ribosylation
of single-stranded DNA gaps promoted their ligation by
ADP-ribose mechanisms and disease 3
DNA ligases even in the absence of ATP, suggesting that
DNA modification “activates” these ends for ligation
(Belousova et al., 2018). However, it is currently unclear if
and how this promotes DNA repair in vivo.
Cellular Functions of ADP-ribosylation
DNA damage signalling and repair
Perhaps the best-studied cellular role of ADP-ribosyl-
ation is the crucial function of PARP1 and PARP2 in pro-
moting the repair of DNA strand breaks (Ray Chaudhuri
and Nussenzweig, 2017). PARP1 is a sensor of DNA
breaks with high affinity for DNA and a lesion recognition
mechanism that allows it to be activated by DNA breaks in-
duced by a broad range of sources (Eustermann et al.,
2015).
PARP1 activation leads to extensive HPF1-assisted
PARylation of chromatin components surrounding DNA
damage sites (Boulikas, 1988; Gibbs-Seymour et al.,
2016). PARylation of histone H1 and all four nucleosomal
histones, as well as HMG proteins, occurs on a number of
modification sites, predominantly serines (Bonfiglio et al.,
2017; Palazzo et al., 2018), but whether these have differ-
ing functions or are simply a chromatin attachment site for
PAR chains is currently unclear. In addition to changes in
the chromatin environment (discussed below), PARylation
leads to the recruitment of a myriad of DNA repair factors,
which often contain dedicated PAR-binding domains such
as BRCT, PBZ, WWE and macrodomain, or a short posi-
tively charged peptide sequence termed the PAR-binding
motif (PBM) (Beck et al., 2014a). Crucially, PARP1 auto-
modification reduces its affinity for DNA, allowing the re-
pair machinery to access the damage site (Satoh and Lin-
dahl, 1992).
In the case of DNA single-strand break repair
(SSBR), PARP1 and PARP2-dependent ADP-ribosylation
leads to the recruitment of the central scaffolding protein
XRCC1, which contains a PAR-binding BRCT domain
(Caldecott, 2008; Breslin et al., 2015; Polo et al., 2019).
Lesions repaired by this pathway arise predominantly from
oxidative damage to the DNA, but are also formed as inter-
mediates of the base excision repair pathway or by the abor-
tive activity of topoisomerases and DNA ligases (Calde-
cott, 2014). XRCC1 interacts with DNA and a range of
DNA modifying enzymes that process these lesions to re-
store canonical 3’OH and 5’P termini required for subse-
quent re-ligation of the damaged strand by DNA ligase III
(Caldecott, 2008; Polo et al., 2019) (Figure 2A).
In cycling cells, this pathway prevents the collision of
unrepaired single-strand breaks (SSBs) with the DNA rep-
lication machinery, which would convert SSBs into much
more deleterious DNA double-strand breaks (DSBs) (Fig-
ure 2B). As these DNA replication-induced DSBs are one-
ended, their accurate repair requires homologous recombi-
nation using the sister chromatid (Saleh-Gohari et al.,
2005; Cortes-Ledesma and Aguilera, 2006). This leads to a
distinctive requirement for functional homologous recom-
bination in cells with defective single-strand break repair,
as discussed in the context of PARP inhibitors below. Inter-
estingly, SSBR was recently shown to serve as a backup
mechanism for the “repair” of unligated Okazaki fragments
during DNA replication (Hanzlikova et al., 2018) and is
also thought to play a role in a sub-pathway of DNA dou-
ble-strand break repair termed microhomology-mediated
end-joining (Sfeir and Symington, 2015).
PARP1 also plays a crucial role in promoting the re-
versal of dysfunctional DNA replication forks (Ray Chau-
dhuri et al., 2012; Ray Chaudhuri and Nussenzweig, 2017).
Fork reversal is an active process that occurs when DNA
replication stalls due to impediments to the progression of
the replisome (Zellweger et al., 2015) and involves the for-
mation of a “chicken foot” structure in which the newly
synthesised daughter strands anneal to each other (Quinet
et al., 2017) (Figure 2C). The molecular mechanisms of this
process are currently under intense investigation, but
PARP1 seems to stabilise reversed forks by preventing the
helicase RECQ1 from dismantling the reversed DNA arm
(Berti et al., 2013).
PARP1 engagement of DNA breaks, particularly
DSBs, has to be carefully coordinated with other end-
binding proteins to ensure genomic stability. The
Ku70/Ku80 heterodimer is a sensor of DSBs for repair by
the non-homologous end-joining pathway (NHEJ) (Shibata
et al., 2018). PARP1 is thought to compete with Ku for
DSB binding so that PARP1 loss allows Ku to engage DNA
ends aberrantly and vice-versa, leading to damage hyper-
sensitivity and genomic instability (Hochegger et al., 2006;
Cheng et al., 2011). This is highlighted by a recent report
suggesting that PARP1 may participate in the eviction of
Ku from breaks that are destined for repair by NHEJ-
independent pathways (Yang et al., 2018). Conversely, the
Mre11/Rad50/Nbs1 (MRN) complex, which also plays a
very early role in the signalling and repair of DSBs, has
been suggested to require PARP1 for its recruitment to
break sites (Haince et al., 2008; Bryant et al., 2009). How-
ever, there are also instances in which PARP1 activation
must be actively suppressed, such as at telomeres, where
the shelterin complex, and in particular TRF2, prevents
PARP1 binding to avoid attempts of “repairing” telomeric
DNA ends (Schmutz et al., 2017).
PARP1 and PARP2 are partially redundant, as illus-
trated by the early embryonic lethality of the double knock-
out mouse (Menissier de Murcia et al., 2003). Pheno-
typically, PARP2 can replace PARP1 for many of the roles
described above, but is restricted in part by a more limited
specificity for DNA breaks with 5’P ends (Langelier et al.,
2014). Both enzymes are redundant for XRCC1 recruit-
ment to oxidative lesions (Hanzlikova et al., 2017) and the
repair of DNA base damage (Ronson et al., 2018), but only
PARP1 seems to generate ADP-ribose in response to topoi-
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Figure 2 - Examples of the impact of ADP-ribosylation in DNA damage signalling and repair. A) Mechanism of single-strand break repair. A single-
strand break activates PARP1/2, leading to HPF-1 assisted PARylation of chromatin. PARP auto-modification causes its release and PAR chains sur-
rounding the break site recruit XRCC1 complex. APTX and PNKP process break termini, Pol fills the gap by DNA synthesis and DNA Ligase III seals
the remaining nick. PARG removes PAR chains and XRCC1 complex is released, completing the repair. B) Defective single-strand break repair causes a
reliance on homologous recombination. An unrepaired single-strand break is encountered by an ongoing replication fork, which converts it into a
one-ended double-strand break. This lesion is repaired by BRCA1 and BRCA2-dependent homologous recombination. C) Role of PARP1/2 in fork rever-
sal. A replication fork encounters an obstacle to its progression and reverts. PARP is activated either by the obstacle/lesion itself or by the DNA end at the
regressed fork. PAR chains prevent RecQ1 binding/activity. Upon resolution of the block, PARP release (and presumably PAR chain degradation by
PARG) allow RecQ1 helicase to access the reversed fork and remodel it back into a canonical replication fork.
somerase poisons (Hoch et al., 2017). Surprisingly, PARP2
seems unable to modify the same target sites as PARP1,
suggesting that this redundancy is indirect (Leslie Pedrioli
et al., 2018). Intriguingly, a recent study suggested that
PARP2 extends PARP1-generated PAR chains, introduc-
ing branching points that are recognised by branching-
specific factors (Chen et al., 2018).
The other DNA-dependent ADP-ribosyl transferase
PARP3, although activated by DNA breaks in vitro, has
less clear roles in DNA repair, and has been implicated in
double-strand break (DSB) repair by non-homologous
end-joining (Rulten et al., 2011), particularly during IgG
class switching (Robert et al., 2015), regulation of DSB re-
pair pathway choice (Beck et al., 2014b) and most recently
the repair of G4-quadruplex containing DNA lesions (Day
et al., 2017; Layer et al., 2018).
ADP-ribosylation also controls telomere length.
TRF1, a telomere-binding protein, is PARylated by the
tankyrase PARP5a (or TNKS1), which reduces its affinity
for the telomere and allows telomerase to access the DNA
end for elongation (Smith et al., 1998). Similarly, PARP2
has been shown to contribute to telomere homeostasis by
modifying TRF2 (Dantzer et al., 2004). Other PARPs, such
as PARP9, PARP10 and PARP15 also play roles in DNA
repair (Yan et al., 2013; Nicolae et al., 2014; Nicolae et al.,
2015), suggesting that the interplay between ADP-ribo-
sylation and genomic stability may be even more extensive
than currently known.
DNA-dependent PARPs and chromatin
PARP1 can be thought of as an integral component of
chromatin that modifies chromatin structure directly (Clark
et al., 2012). For example, PARP1 was shown to compete
with histone H1 for binding to linker DNA (Poirier et al.,
1982; Kim et al., 2004) and is reported to have intrinsic
histone chaperone activity in vitro, mediated in part by the
highly negatively charged nature of the PAR polymer (Mu-
thurajan et al., 2014). This is further illustrated by the ex-
tensive PARP1-dependent modification of core and linker
histones (Boulikas, 1988), as well as the existence of H2A
variants with PAR-binding domains that may well mediate
long-range PARP-dependent chromatin interactions (Ti-
minszky et al., 2009).
PARP1 also regulates chromatin accessibility indi-
rectly by recruiting chromatin remodellers, such as ALC1,
SMARCA5 and CHD2 (Ahel et al., 2009; Smeenk et al.,
2013; Luijsterburg et al., 2016). Interestingly, processing
of PARP1-generated PAR chains by PARG and NUDIX5
hydrolases has been suggested to provide a localised pool
of ATP in the nucleus for ATP-consuming chromatin re-
modelling complexes (Wright et al., 2016). PARP1 activa-
tion at gene promoters also controls the induction of trans-
cription, such as chromatin “puffing” of heat
shock-inducible genes in Drosophila polytene chromo-
somes (Tulin and Spradling, 2003), and at gene promoters
responsive to transcription factors such as NFB, PPAR
and hormone receptors such as ER, AR and RAR (Kraus
and Hottiger, 2013). Recently, PARP1 has also been linked
with the regulation of RNA polymerase II pausing via the
negative elongation factor NELF-E (Gibson et al., 2016).
However, a more precise understanding of the molecular
mechanisms involved in most of these processes and recon-
ciliation with the fact that PARP1 KO mice have very mild
phenotypes are still lacking.
Although the partial redundancy between PARP1 and
PARP2 is clear for DNA damage-related functions,
whether this extends to chromatin remodelling and trans-
criptional regulation is unclear. A screen for PARP2 targets
revealed an enrichment of proteins associated with trans-
criptional regulation and RNA splicing, suggesting this
might be the case. Similarly, targets of PARP3 were en-
riched in RNA processing, transcription and chromatin or-
ganization (Bartolomei et al., 2016), suggesting that all
three DNA-dependent PARPs may well be involved in im-
portant DNA-damage independent aspects of chromatin bi-
ology.
ADP-ribose in cellular signalling
ADP-ribosylation is also involved in controlling sev-
eral signalling cascades, such as Wnt/-catenin, NFB and
the unfolded protein response. The two tankyrases PARP5a
and PARP5b (TNKS1 and TNKS2) PARylate axin, a cen-
tral component in the -catenin destruction complex, lead-
ing to its proteasomal degradation via RNF146, a PAR-
dependent E3 ubiquitin ligase (Huang et al., 2009). Wnt
signalling is further promoted by PARP10-dependent
mono-ADP-ribosylation of GSK3, which inhibits its kina-
se activity and also stabilises -catenin (Feijs et al., 2013).
PARP10 additionally suppresses NFB signalling via
MARylation and inactivation of NEMO (Verheugd et al.,
2013), and PARP16 was shown to MARylate and activate
PERK and IRE1, central signalling hubs in the unfolded
protein response in the endoplasmic reticulum (Jwa and
Chang, 2012).
Many PARPs are involved in cellular antiviral mech-
anisms, with PARP7, PARP9, PARP12 and PARP14 all
implicated in the interferon response, and PARP13 is in-
volved in direct degradation of viral transcripts (Atasheva
et al., 2014; Welsby et al., 2014; Zhang, Y. et al., 2015;
Iwata et al., 2016). Intriguingly, many of these enzymes, as
well as PARP4 and PARP15, are under diversifying selec-
tive pressure in primates, suggesting an ADP-ribose
“arms-race” between hosts and viral pathogens (Daugherty
et al., 2014).
With the recent development of better tools to detect
ADP-ribose modification of proteins (Chang, 2018), many
additional roles of ADP-ribosylation in a variety of cellular
signalling pathways are likely to emerge in coming years.
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PARP1 and cell death
Active PARP1 produces large amounts of PAR and at
high levels of DNA damage up to 80% of the cellular NAD+
pool can be depleted within 5–15 min (D’Amours et al.,
1999). Since NAD+ is necessary for glyceraldehyde 3-
phosphate dehydrogenase activity during glycolysis (Tan et
al., 2013), a reduction in NAD+ leads to lower pyruvate
production, reducing carbon flow into the mitochondrial
TCA cycle, and hence ATP production. Conversely, ATP is
required for NAD+ synthesis, and therefore the uncon-
trolled use of NAD+ by PARP1 can lead to a bioenergetic
collapse (Figure 3).
PARP1 hyperactivation initiates a programmed cell
death pathway termed parthanatos, which is independent of
canonical apoptosis, necrosis or autophagy (Yu et al., 2002;
Galluzzi et al., 2018) and is mediated by the apoptosis-
inducing factor (AIF) (Yu et al., 2002; Andrabi et al., 2006)
(Figure 3). AIF is a mitochondrial membrane-anchored
protein that is required for the assembly of the mitochon-
drial electron transport chain and exists in an equilibrium
between monomeric and dimeric forms, with NAD(H) bin-
ding favouring dimer formation (Brosey et al., 2016). Upon
PARP1 hyperactivation, AIF is released from the mito-
chondria and translocates to the nucleus to drive partha-
natos (Yu et al., 2002; Otera et al., 2005). How this occurs
is currently unclear, but surprisingly, the AIF transmem-
brane fragment does not need to be cleaved (Wang, Y. et
al., 2009). One possibility is that NAD+ depletion itself pro-
motes AIF release either by mitochondrial dysfunction
(Alano et al., 2010; Baxter et al., 2014) or by inducing
conformational changes in AIF (Sevrioukova, 2009; Bro-
sey et al., 2016). Alternatively, a direct interaction between
AIF and protein-free PAR polymers has been suggested to
mediate AIF release (Andrabi et al., 2006; Wang, Y. et al.,
2011). Free AIF then promotes translocation of the nu-
clease MIF to the nucleus, which cleaves genomic DNA in-
ducing cell death (Wang, Y. et al., 2016a) (Figure 3). Many
of the molecular mechanisms of parthanatos remain to be
clarified, but an improved understanding of this pathway is
critical for the development of novel treatment avenues for
a potentially large number of diseases (see below).
Human diseases and therapeutic opportunities
PARP1/2 inhibition and HR-defective cancer
DNA-activated PARPs, particularly PARP1, became
attractive drug target candidates for cancer therapy in 2005
when PARP inhibition (PARPi) was shown to induce syn-
thetic lethality in cells lacking BRCA1/2 (Bryant et al.,
2005; Farmer et al., 2005). As discussed above, in the ab-
sence of PARP1-dependent SSBR, unrepaired single-
strand breaks are converted into DSBs by the passage of a
replication fork, leading to a distinct requirement for
BRCA1/2-dependent homologous recombination (HR)
(Figure 2B). BRCA genes are tumour suppressors that are
frequently mutated in breast and ovarian cancers, and four
compounds (rucaparib, niraparib, olaparib and talazoparib)
are currently licenced by the U.S. Food and Drug Adminis-
tration (FDA) for treatment of BRCA-defective cancers
(O’Connor, 2015; Bitler et al., 2017). These inhibitors bind
to the nicotinamide binding site in the catalytic domain,
mimicking the three H-bonds established by the nicoti-
namide group from NAD+. By blocking PARP catalytic ac-
tivity, these compounds slow single-strand break repair in
two ways: a) the lack of PARylation surrounding break
sites delays the recruitment of DNA repair factors such as
XRCC1; and b) by preventing PARP1 auto-modification
that is required for release of the protein from the DNA
break (D’Amours et al., 1999). Thus, these inhibitors lock
or “trap” the enzyme bound to the DNA, preventing the ac-
cess of other enzymes to the break (Bryant et al., 2005;
Pommier et al., 2016; Lord and Ashworth, 2017). Novel in-
hibitors that induce more stable trapping of PARP seem to
be better inducers of synthetic lethality in BRCA-mutated
cells, suggesting that this trapping effect is crucial for
PARP inhibitor efficacy (Murai et al., 2014).
The clinical success of PARP inhibitors in
BRCA1/2-mutated breast and ovarian cancers has ignited a
push for more widespread use of these compounds in can-
cers with a molecular signature of defective HR, irrespec-
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Figure 3 - PARP1 mediates cell death by Parthanatos. Oxidative damage
triggers PARP-hyperactivation, resulting in AIF release from the mito-
chondria and nuclear translocation of the AIF/MIF complex. Endonu-
clease activation causes cell death. Some of the potential therapeutic tar-
gets are depicted in red. The nucleus is coloured in grey and cytoplasm in
orange. AIF: Apoptosis Inducing Factor. MIF: macrophage migration in-
hibitory factor.
tive of which HR gene is mutated and in which tissue the
tumour originated (Pilie et al., 2019). Similarly, novel in-
hibitors that selectively target different PARPs, including
PARP3, PARP5a/5b, PARP7, PARP10, PARP11 and
PARP14 are under investigation for the targeted treatment
of cancers with alterations in particular pathways (Ishida et
al., 2006; Lindgren et al., 2013; Iwata et al., 2016; Wang,
Y. Q. et al., 2016b; Ferri et al., 2017; Yoneyama-Hirozane
et al., 2017; Kirby et al., 2018; Moustakim et al., 2018;
Murthy et al., 2018).
Remarkably, PARP1 inhibitors may also be of signif-
icant therapeutic value for non-oncological use both in rare
neurological disorders in which excessive PARP signalling
seems to be detrimental, as well as in more prevalent degen-
erative diseases in which parthanatos seems to play a cen-
tral pathological role (Berger et al., 2018) (discussed
below).
ADP-ribosylation in genetic neurodegenerative
disorders
Mutations in single-strand break repair genes, such as
PNKP, APTX, TDP1 and XRCC1, cause genetic neuro-
degenerative disorders characterised by severe cerebellar
atrophy and ataxia (Moreira et al., 2001; El-Khamisy et al.,
2005; Bras et al., 2015; Hoch et al., 2017). Treatment of
cells from these patients with DNA damaging agents leads
to excessive PARP1 activation, suggesting that defective
single-strand break repair leads to overt signalling of these
lesions (Hoch et al., 2017). As deletion of PARP1 partially
rescued many of the cerebellar defects observed in
XRCC1-deficient mice, it was suggested that PARP1-in-
duced parthanatos and/or NAD+ depletion contributes to
disease pathology (Hoch et al., 2017). Although PARP1 in-
hibition should in principle be beneficial in this scenario,
the currently available PARP1 inhibitors are unlikely to be
of therapeutic value, as the PARP1 trapping effect (dis-
cussed above) further compounds the DNA repair defect in
these cells (Hoch et al., 2017). In this context, inhibitors
that better mimic genetic deletion of PARP1 would be de-
sirable.
Mutations in enzymes involved in removing ADP-
ribose modifications also leads to neurodegenerative dis-
ease, as illustrated by the identification of patients with mu-
tations in the hydrolases ARH3 and TARG. ARH3 has
specificity for both poly-ADP-ribose chains as well as
mono-ADP-ribose moieties attached to serines (Abplanalp
et al., 2017; Fontana et al., 2017), whereas TARG hydroly-
ses the ester linkage between mono-ADP-ribose and aspar-
tate or glutamate side chains (Sharifi et al., 2013). ARH3
mutations are associated with neurodegenerative defects
such as ataxia and febrile seizures, while TARG1 loss
causes severe developmental delay, epilepsy and quadri-
plegia (Sharifi et al., 2013; Danhauser et al., 2018; Ghosh
et al., 2018). Whereas TARG deficient cells shown signs of
DNA-repair defects, a role for ARH3 in DNA damage re-
sponses is speculative at this point, although serine has
been recently established as the primary acceptor of DNA
damage-induced ADP-ribosylation (Palazzo et al., 2018).
If excessive PAR formation, NAD+ depletion and/or par-
thanatos are also involved in promoting the neurological
defects seen in these patients, currently available catalytic
PARP1 inhibitors may well be a viable therapeutic option
(Danhauser et al., 2018; Ghosh et al., 2018).
Mutations in PARP10 lead to a neurodegenerative
disorder associated with developmental delay and cortical
atrophy, as well as delayed myelination (Shahrour et al.,
2016). Although a defect in PARP10-dependent Wnt or
NFB signalling was not determined, patient cells had a
DNA repair defect in response to hydroxyurea (HU) and ul-
traviolet light (UV), and the pathology is reminiscent of
other DNA repair disorders (Shahrour et al., 2016). A more
detailed understanding of the cellular consequences of
PARP10 loss and which of its many functions is most im-
portant to prevent disease onset and progression will be
critical to suggest possible therapeutic avenues for this dis-
ease.
Parthanatos inhibition
PARP1-dependent cell death via parthanatos has
been implicated in several critical pathological processes,
such as ischemia-reperfusion injury in myocardial infarc-
tion and stroke, septic shock, brain trauma and neurodege-
nerative diseases such as Parkinsons disease and Alzhei-
mers disease (Pacher and Szabo, 2007; Moroni, 2008; Lee
et al., 2013; Dawson and Dawson, 2017; Berger et al.,
2018; Henning et al., 2018; Kam et al., 2018; Zhang, J. et
al., 2018). A common theme among these disorders seems
to be PARP1 hyperactivation in response to oxidative DNA
damage, either as part of the reperfusion of oxygen-de-
prived tissues or caused by pathophysiological changes that
induce the production of reactive oxygen species or nitric
oxide.
Interestingly, PARP1 cytotoxicity seems to have a
gender bias (McCullough et al., 2005; Yuan et al., 2009),
with androgens promoting parthanatos (Vagnerova et al.,
2010; Sharma et al., 2011), while oestrogens counteract it
(Batnasan et al., 2015). This raises the fascinating possibil-
ity that differential sensitivity to PARP1 hyperactivation
might contribute to the higher male incidence of ischaemic
stroke, sepsis and Parkinsons disease (Miller and Cronin-
Golomb, 2010; Sakr et al., 2013; Barker-Collo et al., 2015).
Mounting pre-clinical evidence suggests that PARP1
knockout or PARP inhibitor treatment have profound bene-
ficial effects in mouse models of parthanatos-induced pa-
thologies, preventing cell death and tissue dysfunction
(Pacher and Szabo, 2007; Dawson and Dawson, 2017;
Berger et al., 2018; Henning et al., 2018). These results
have prompted calls for clinical trials to repurpose PARP
inhibitors for the treatment of these disorders, particularly
when no other viable treatment option exists (Berger et al.,
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2018). Conceptually, targeting other steps in parthanatos,
such as preventing mitochondrial AIF release or inhibiting
nuclear import or activation of the MIF nuclease may also
be of therapeutic value (Figure 3). Although these com-
pounds would have to undergo extensive pre-clinical and
clinical efficacy and safety trials, their development may be
warranted by a reduced potential for DNA repair-associa-
ted side-effects of systemic PARP inhibition during
chronic treatment.
Concluding remarks
Detailed knowledge of the processes and pathways
regulated by post-translational modifications such as phos-
phorylation and ubiquitination led to the development of a
myriad of kinase inhibitors and molecules targeting the
ubiquitin system, either already in clinical use or in clinical
trials (Ferguson and Gray, 2018; Wertz and Wang, 2019).
In recent years, novel tools to study ADP-ribosylation have
allowed a rapid development in this field, characterising
many of the “writers”, “erasers” and “readers” of this modi-
fication. Taken together with the fact that the first PARP
inhibitor only entered the clinic in 2014, this raises the ex-
citing prospect that a more detailed understanding of
ADP-ribose metabolism, particularly of less well-studied
PARPs and hydrolases, may well yield novel therapeutic
strategies in coming years.
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